Abstract | BACKGROUND: PATIENTS AND METHODS: Seventeen patients with previously untreated unresectable hepatocellular carcinoma were enrolled on the study. Edatrexate, 80 mg/m2 weekly for 5 weeks, was administered intravenously. The treatment course was repeated every 6 weeks. Tumor response was evaluated by computerized tomographic scan after 2 courses. RESULTS: CONCLUSIONS:
|
Authors | R Pazdur, D F Moore, B Bready, L Giannone, A Maldonado, Y G Lin, R H Fueger, R J Winn, B Levin |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 5
Issue 7
Pg. 646-8
(Sep 1994)
ISSN: 0923-7534 [Print] England |
PMID | 7527654
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Folic Acid Antagonists
- alpha-Fetoproteins
- edatrexate
- Aminopterin
|
Topics |
- Adult
- Aged
- Agranulocytosis
(chemically induced)
- Aminopterin
(adverse effects, analogs & derivatives, therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Carcinoma, Hepatocellular
(blood, drug therapy)
- Female
- Folic Acid Antagonists
(adverse effects, therapeutic use)
- Humans
- Liver Neoplasms
(blood, drug therapy)
- Male
- Middle Aged
- Remission Induction
- Thrombocytopenia
(chemically induced)
- alpha-Fetoproteins
(metabolism)
|